Recent advances in the development of γ-secretase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 513-525

  Josien, Hubert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

secretase; A ; Alzheimer's disease; Amyloid precursor protein; Notch; Presenilin

Indexed keywords

ALDEHYDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CAPROLACTAM DERIVATIVE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; KETONE DERIVATIVE; L 682679; L 684414; L 685458; LETEPRINIM; LY 374973; LY 411575; NOTCH RECEPTOR; PEPTIDE DERIVATIVE; PRESENILIN 1; PRESENILIN 2; SUCCINIMIDE DERIVATIVE; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; PROTEINASE; PROTEINASE INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE; ANIMAL; CHEMISTRY; ENZYMOLOGY; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; ENDOPEPTIDASES; HUMANS; PROTEASE INHIBITORS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036653703     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. McDowell I: Alzheimer's disease: Insights from epidemiology. Aging (2001) 13:143-162.
2. Emre M, Qizilbash N: Experimental approaches and drugs in development for the treatment of dementia. Expert Opin Investig Drugs (2001) 10:607-617. This review summarizes the therapeutic approaches currently under investigation for the treatment of AD.
3. Greenlee W, Clader J, Asberom T, McCombie S, Ford J, Guzik H, Kozlowski J, Li S, Liu C, Lowe D, Vice S, Zhao H, Zhou G, Billard W, Binch H, Crosby R, Duffy R, Lachowicz J, Coffin V, Watkins R, Ruperto V, Strader C, Taylor L, Cox K: Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco (2001) 56:247-250.
4. Eglen RM, Choppin A, Watson N: Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci (2001) 22:409-414.
5. Clader JW: Recent advances in cholinergic drugs for Alzheimer's disease. Curr Opin Drug Discovery Dev (1999) 2:311-320.
6. Selkoe DJ: The origins of Alzheimer disease: A is for amyloid. J Am Med Assoc (2000) 283:1615-1617. This article summarizes the evidence in support of the amyloid hypothesis.
7. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J Am Med Assoc (2000) 283:1571-1577. One of the most emphatic studies to date to suggest that high levels of Aβ contribute to AD onset.
8. Combs CK, Karlo JC, Kao S-C, Landreth GE: β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci (2001) 21:1179-1188.
9. Jhee S, Shiovitz T, Crawford AW, Cutler NR: β-Amyloid therapies in Alzheimer's disease. Expert Opin Investig Drugs (2001) 10:593-605. This review summarizes the current approaches aimed at reducing Aβ secretion, and covers other strategies such as immunization therapy.
10. Moore CD, Wolfe MS: Inhibition of β-amyloid formation as a therapeutic strategy. Exp Opin Ther Pat (1999) 9:135-146.
11. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177. First report on the efficacy of immunization therapy in preventing plaque formation and reducing AD behavioral impairments in PDAPP transgenic mice.
12. Steinberg D: Companies halt first Alzheimer vaccine trial. The Scientist (2002) 16:22-23.
13. Talaga P: β-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: Dream or reality? Mini Rev Med Chem (2001) 1:175-186.
14. Thomas T, Nadackal TG, Thomas K: Aspirin and nonsteroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport (2001) 12:3263-3267.
15. Wolfe MS: Secretase targets for Alzheimer's disease: Identification and therapeutic potential. J Med Chem (2001) 44:2039-2060. A comprehensive review on AD and APP secretases that details the pharmacological characterization of each β- and γ-secretase and the elements supporting the hypothesis that presenilin is γ-secretase (an aspartyl protease), as well as proposing a model for the γ-secretase active site. This review also covers some of the current inhibitors under investigation.
16. Olson RE, Copeland RA, Seiffert D: Progress towards testing the amyloid hypothesis: Inhibitors of APP processing. Curr Opin Drug Discovery Dev (2001) 4:390-401. Recent review on APP secretases and β- and γ-secretase inhibitors.
17. Slack BE, Ma LK, Seah CC: Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme. Biochem J (2001) 357:787-794.
18. Buxbaum JD, Liu K-N, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA: Evidence that tumor necrosis factor-α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 273:27765-27767.
19. Lopez-Perez E, Zhang Y, Frank SJ, Creemers J, Seidah N, Checler F: Constitutive α-secretase cleavage of the β-amyloid precursor protein in the furin-deficient LoVo cell line: Involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10. J Neurochem (2001) 76:1532-1539.
20. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA (2001) 98:5815-5820.
21. Wolozin B, Kellman W, Ruosseau P, Celesia GC, Siegel G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol (2000) 57:1439-1443.
22. Vassar R: The β-secretase, BACE: A prime drug target for Alzheimer's disease. J Mol Neurosci (2001) 17:157-170. A comprehensive review on the characterization of BACE1 and BACE2 secretases, including a summary of knockout studies that suggest a therapeutic potential for BACE1 inhibitors.
23. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J: Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (2000) 290:150-153. Reports the high-resolution structure of the protease domain of BACE complexed with a nanomolar potency inhibitor.
24. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis J-C, Yan Q, Richards WG, Citron M, Vassar R: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci (2001) 4:231-232.
25. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John, V: Design of substrate-based inhibitors of human β-secretase. J Med Chem (2002) 45:259-262.
26. Fraser PE, Yang D-S, Yu G, Levesque L, Nishimura M, Arawaka S, Serpell LC, Rogaeva E, St George-Hyslop P: Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta (2000) 1502:1-15. Includes a comprehensive list of presenilin mutations associated with FAD early onset.
27. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS: Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci USA (2002) 99:2720-2725.
28. Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B: Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron (2001) 32:579-589. Propose a ring-like structure for the PS1 binding pocket in which binding and cleavage of C99 constitute two separate events.
29. Selkoe DJ, Wolfe MS: In search of γ-secretase: Presenilin at the cutting edge. Proc Natl Acad Sci USA (2000) 97:5690-5692. This review summarizes the evidence connecting presenilin to γ-secretase activity.
30. Herreman A, Semeels L, Annaert W, Collen D, Schoonjans L, De Strooper B: Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol (2000) 2:461-462.
31. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA: Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch1. Nat Cell Biol (2000) 2:463-465.
32. Zhang L, Song L, Terracina G, Liu Y, Pramanik B, Parker E: Biochemical characterization of the γ-secretase activity that produces β-amyloid peptides. Biochemistry (2001) 40:5049-5055. Description of a cell-free γ-secretase assay.
33. Li Y-M, Xu M, Lai M-T, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi X-P, Yin K-C, Shafer JA, Gardell SJ: Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405:689-694. Provides evidence that an ethylenehydroxy γ-secretase inhibitor binds directly to PS1.
34. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai J-Y, Rahmati T, Xia W, Selkoe DJ, Wolfe MS: Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2:428-434. Provides evidence that a difluoroethylenealcohol γ-secretase inhibitor binds directly to PS1.
35. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R: Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J Biol Chem (2000) 275:34086-34091. Provides evidence that a small molecule γ-secretase inhibitor binds directly to PS1 and PS2. Describes the γ-secretase inhibitory potency of proprietary compounds from Elan and DuPont as measured in a cell-free assay.
36. Moore CL, Leatherwood DD, Diehl TS, Selkoe DJ, Woffe MS: Difluoro ketone peptidomimeties suggest a large S1 pocket for Alzheimer's γ-secretase: Implication for inhibitor design. J Med Chem (2000) 43:3434-3442.
37. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry (2000) 39:8698-8704.
38. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature (1999) 398:513-517. One of the first reports to suggest that presenilin-1 is an essential cofactor for γ-secretase activity or is itself γ-secretase, a transmembrane aspartyl protease.
39. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ: The transmembrane aspartates in presenilin 1 and 2 are obligatory for γ-secretase activity and amyloid β-protein generation. J Biol Chem (2000) 275:3173-3178.
40. Levitan D, Lee J, Song L, Manning R, Wong G, Parker E, Zhang L: PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling. Proc Natl Acad Sci USA (2001) 98:12186-12190.
41. Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C: Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch. Nat Cell Biol (2000) 2:205-211.
42. Durkins JT, Murphy S, Husten EJ, Trusko SP, Savage MJ, Rotella DP, Greeberg BD, Siman R: Rank-order of potencies for inhibition of the secretion of Aβ40 and Aβ42 suggests that both are generated by a single γ-secretase. J Biol Chem (1999) 274:20499-20504.
43. Higaki JN, Chakravarty S, Bryant CM, Cowart LR, Harden P, Scardina JM, Mavunkel B, Luedtke GR, Cordell B: A combinatorial approach to the identification of dipeptide aldehyde inhibitors of β-amyloid production. J Med Chem (1999) 42:3889-3898.
44. Campbell WA, Iskandar M-K, Reed MLO, Xia W: Endoproteolysis of presenilin in vitro: Inhibition by γ-secretase inhibitors. Biochemistry (2002) 41:3372-3379. This report leads to the suggestion that presenilinase activity could be regulated separately from γ-secretase activity.
45. Beher D, Wrigley JDJ, Nadin A, Evin G, Masters CL, Harrison T, Castro JL, Shearman MS: Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor: Implications for presenilin biology. J Biol Chem (2001) 276:45394-45402. This report leads to the suggestion that presenilinase activity could be regulated separately from γ-secretase activity.
46. Bakshi P, Diehl TS, Wolfe MS: γ-Secretase tolerates both D and L amino acids in (hydroxyethyl)urea peptidomimetics. 223rd ACS Meeting, Orlando, FL, USA (2002):MEDI-038.
47. Felsenstein KM: Aβ modulation: The beginning of the end or the end of the beginning. IBC Ninth Annual Alzheimer's Meeting, Atlanta, GA, USA (2001). Presentation of a potent and orally bioavailable inhibitor.
48. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJS, Lile JD, Citron M: Fenchylamine sulfonamide inhibitors of amyloid β peptide production by the γ-secretase proteolytic pathway: Potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem (2000) 43:2297-2299.
49. May PC: Marked reduction of Aβ accumulation and β-amyloid plaque pathology in mice upon chronic treatment with a functional γ-secretase inhibitor. 31st Annual Society of Neuroscience Meeting, San Diego, CA, USA (2001). Presentation of a highly potent and orally bioavailable inhibitor that is effective at reducing plasma and cortical Aβ in transgenic pre-plaque mice with no apparent side effects with up to 90 days dosing.
50. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL et al: Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem (2001) 76:173-181. First demonstrated efficacy of a γ-secretase inhibitor in reducing Aβ brain levels in mice.
51. Wolfe MS: γ-Secretase/presenilin inhibitor causes Notch-deficient phenotype in Drosophila. 31st Annual Society of Neuroscience, San Diego, CA, USA (2001).
52. Hartmann D, Toumoy J, Saftig P, Annaert W, De Strooper B: Implication of APP secretases in Notch signaling. J Mol Neurosci (2001) 17:171-181. A comprehensive review of the Notch signaling system that covers the role and importance of presenilins in Notch1 cleavage and describes the pathological consequences of Notch signaling malfunction.
53. Berezovska O, Jack C, Deng A, Gastineau N, Rebeck GW, Hyman BT: Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent γ-secretase cleavage. J Biol Chem (2001) 276:30018-30023.
54. Petit A, St George-Hyslop P, Fraser P, Checler F: γ-Secretase-like cleavages of Notch and βAPP are mutually exclusive in human cells. Biochem Biophys Res Commun (2002) 290:1408-1410. Description of a Notch processing cell-based assay.
55. Ni C-Y, Murphy MP, Golde TE, Carpenter G: γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294:2179-2181.
56. Lee H-J, Jung K-M, Huang YZ, Bennett LB, Lee JS, Mei L, Kim T-W: Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol Chem (2002) 277:6318-6323.
57. Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, Schroeter EH, Kopan R: γ-Secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA (2001) 98:7487-7491.
58. Doerfler P, Shearman MS, Perlmutter RM: Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc Natl Acad Sci USA (2001) 98:9312-9317.
59. Berechid BE, Kitzmann M, Foltz DR, Roach AH, Seiffert D, Thompson LA, Olson RE, Bemstein A, Donoviel DB, Nye JS: Identification and characterization of presenilinin-dependent Notch signaling. J Biol Chem (2002) 277:8154-8165.
60. Petit A, Bihel F, Alves da Costa C, Pourquie O, Checler F, Kraus J-L: New protease inhibitors prevent γ-secretase mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol (2001) 3:507-511. Description of a Notch processing cell-based assay.
61. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98:8850-8855. One of the first reports to suggest that clearance of plasma Aβ could reduce brain Aβ burden by acting as a peripheral sink.
62. TAKEDA CHEMICAL INDUSTRIES LTD (Miyamoto M, Matsui J, Fukumoto H, Tarui N): β-secretase inhibitors. WO-00187293 (2001).
63. BRIGHAM & WOMEN'S HOSPITAL INC (Wolfe MS, Selkoe DJ): (Hydroxyethyl)ureas as inhibitors of Alzheimer's β-amyloid production. WO-00214264 (2002).
64. MERCK & CO/BRISTOL-MYERS SQUIBB CO (Smith DW, Munoz B, Srinivasan K, Bergstrom CP, Chaturvedula PV, Deshpande MS, Keavy DJ, Lau WY, Parker MF, Sloan CP, Wallace OB, Wang HH): Novel sulfonamide compounds and their uses thereof. WO-00050391 (2000). Patent covering a wide range of arylsulfonamides which may be related to a candidate from Bristol-Myers Squibb that was reported to have entered phase I clinical trials.
65. MERCK SHARP & DOHME LTD (Belanger PC, Collins IJ, Hannam JC, Harrison T, Lewis SJ, Madin A, McIver EG, Nadin AJ, Neduvelil JG, Shearman MS, Smith AM, Sparey TJ, Stevenson GI, Teall MR): Sulphonamido-substituted bridged bicycloalkyl derivatives. WO-00170677 (2001).
66. ELI LILLY & CO/ATHENA NEUROSCIENCE INC (Wu J, Tung JS, Thorsett ED, Pleiss MA, Nissen JS, Neitz J, Latimer LH, John V, Freedman S, Britton TC, Audia JE et al): Cycloalkyl, lactam, lactone and related compounds pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds. WO-09828268 (1998). Patent covering a series of caprolactams, including LY-411575.
67. DUPONT PHARMACEUTICALS CO (Olson RE, Maduskuie TP, Thompson LA, Tebben AJ, Wang N, Deng W, Liu H): Succinoylamino carbocycles and heterocycles as inhibitors of Aβ protein production useful for treating Alzheimer's disease. WO-00160826 (2001).
68. DUPONT PHARMACEUTICALS CO (Olson RE): Lactams substituted by cyclic succinates as inhibitors of Aβ protein production. WO-00192235 (2001).
69. DUPONT PHARMACEUTICALS CO (Olson RE, Yang MG): Cyclic lactams as inhibitors of Aβ protein production. WO-00174783 (2001).
70. DUPONT PHARMACEUTICALS CO (Yang MG, Liu H): Cyclic lactams as inhibitors of Aβ protein production. WO-00174784 (2001).
71. DUPONT PHARMACEUTICALS CO (Olson RE, Liu H, Thompson LA): Hydroxyalkanoyl aminolactams and related structures as inhibitors of Aβ protein production. WO-00119797 (2001).
72. DUPONT PHARMACEUTICALS CO (Han W, Liu H, Olson RE, Yang MG): Substituted lactams as inhibitors of Aβ protein production. WO-00177086 (2001).
73. DUPONT PHARMACEUTICALS CO (Thompson LA, Han AQ): Amino lactam sulfonamides as inhibitors of Aβ protein production. WO-00127108 (2001).
74. MERCK SHARP & DOHME LTD (Castro Pineiro JL, Churcher I, Guiblin AR, Harfison T, Kerrad S, Madin A, Nadin AJ, Owens AP, Sparey TJ, Teall MR, Williams S): Benzodiazepine derivatives as APP modulators. WO-00190084 (2001).
75. BRISTOL-MYERS SQUIBB CO (Chaturvedula PV, Yeola S, Vig S): Benzodiazepinone β-amyloid inhibitors: Arylacetamidoalanyl derivatives. US-2002002621 (2002).
76. DUPONT PHARMACEUTICALS CO (Thompson LA): Lactams as inhibitors of A-β protein production. WO-00172324 (2001).
77. MERCK & CO (Teall MR): γ-Secretase inhibitors. US-20020013315 (2002).